Conte, Pierfranco

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 3,294

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 2,622

Ribociclib as first-line therapy for HR-positive, advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 2,039

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial

Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 991

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 876

OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 779

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 624

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

Conte, P., & Guarneri, V. (2004) · The Oncologist

Bone health and treatmentsBone health and osteoporosis research

Cited by 241

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Rugo, H. S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S. M., Jurado, J. C., Juric, D., Mayer, I., Ciruelos, E. M., et al. (2020) · Annals of Oncology

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 193

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

Juric, D., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H., Iwata, H., Conte, P., Mayer, I., Kaufman, B., et al. (2019) · Cancer Research

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 62

MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma

Rossignoli, F., Spano, C., Grisendi, G., Foppiani, E. M., Golinelli, G., Mastrolia, I., Bestagno, M., Candini, O., Petrachi, T., Recchia, A., et al. (2019) · Theranostics

Pancreatic and Hepatic Oncology ResearchBacterial Cancer Therapy

Cited by 55

LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab

Bonanno, L., De Paoli, A., Zulato, E., Esposito, G., Calabrese, F., Favaretto, A., Santo, A., Conte, A. D., Chilosi, M., Oniga, F., et al. (2017) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 53

Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas

Grisendi, G., Spano, C., D'souza, N., Rasini, V., Veronesi, E., Prapa, M., Petrachi, T., Piccinno, S., Rossignoli, F., Burns, J. S., et al. (2015) · STEM CELLS

Mesenchymal stem cell researchSarcoma Diagnosis and Treatment

Cited by 48

Olaparib efficacy in patients with germline BRCA ‐mutated, HER2 ‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial

Senkus, E., Delaloge, S., Domchek, S. M., Conte, P., Im, S., Xu, B., Armstrong, A., Masuda, N., Fielding, A., Robson, M., et al. (2023) · International Journal of Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 39

Abstract CT142: Prevalence of PIK3CA mutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial

Rugo, H. S., Mayer, I., Conte, P., Loibl, S., Campone, M., Juric, D., Andre, F., Fritzemeier, M., He, W., Babbar, N., et al. (2019) · Cancer Research

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 17

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations

Frega, S., Lorenzi, M., Fassan, M., Indraccolo, S., Calabrese, F., Favaretto, A., Bonanno, L., Polo, V., Zago, G., Lunardi, F., et al. (2017) · Oncotarget

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 17